The World Health Organization (WHO) is aware on Monday that many are waiting for organizations to recommend that Bharat Biotech’s cavaxin be on the Covid-19 Emergency Use List (EUL). As I said, it can never be cut short.
In a tweet, WHO explained that organizations need to “thoroughly evaluate to ensure they are safe and effective” before recommending products for emergency use.
In another tweet, WHO reported that Covaxin manufacturer Bharat Biotech regularly submits data to WHO, and WHO experts have reviewed this data. “WHO is looking forward to one more piece of information from the company today,” said WHO.
Organizations, the time frame of the WHO EUL procedure, is how quickly vaccine manufacturers need the data that WHO needs to assess the quality, safety, efficacy, and suitability of vaccines for low and middle incomes. I explained that it depends on whether it can be provided. Country.
“When the information provided addresses, all questions raised, WHO and the Technical Advisory Group will complete the assessment and reach a final recommendation on whether to give the vaccine an emergency use list,” WHO said. I did.
Earlier on Sunday, WHO Chief Scientist Soumya Swaminathan said the organization’s technical advisory group would meet on October 26 to review the Covaxin Emergency Use List (EUL).
“The Technical Advisory Group will meet on October 26 to review # Covaxin’s EUL. @ WHO is working closely with @BharatBiotech to complete the documentation. Our goal is to approve emergency use. With a broad portfolio of vaccines, the population is ubiquitous, “Swaminasan tweeted on Sunday.
Read also: WHO says it may be the “last chance” to form a new advisory group and find the origin of COVID-19
Read also: WHO considers emergency listing of Covaxin on October 26
“I can’t cut corners”: WHO on the emergency list of Covaxin vaccines from Barrat Biotech
Source link “I can’t cut corners”: WHO on the emergency list of Covaxin vaccines from Barrat Biotech